Stemline Therapeutics (STML) Files $50M IPO
Tweet Send to a Friend
In a Form S-1 late Monday, Stemline Therapeutics (Nasdaq: STML) registered a $50 million initial public offering. The company plans to list on the NASDAQ under the symbol "STML."
The offering is being made through Oppenheimer and JMP Securities.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The offering is being made through Oppenheimer and JMP Securities.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Preliminary Russell 3000 Addition Pushing Stocks Around
- A Sale or an IPO for Nokia Siemens Networks? (NOK)
- CDW Corp (CDW) Commences IPO; Will Sell 27.9M Common Shares
Create E-mail Alert Related Categories
IPOsRelated Entities
JMP Securities, S1
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
